Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3422]

The parotid gland; an unusual site of colorectal cancer metastasis

Dr Paula Isabel Franco - St Luke’s Medical Center, Malina, Philippines

The parotid gland; an unusual site of colorectal cancer metastasis ( Dr Paula Isabel Franco - St Luke’s Medical Center, Malina, Philippines )

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine...

Dr Lin-Quan Tang - Sun Yat-sen University, Guangzhou, China

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine improves PFS in N2-3 nasopharyngeal carcinoma ( Dr Lin-Quan Tang - Sun Yat-sen University, Guangzhou, China )

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in firstline HRR mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

CDK4/6 inhibitors added to first line show no greater benefit when compared to...

Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands

CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC ( Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands )

Dostarlimab chemo combination for primary advanced or recurrent endometrial...

Prof Matthew Powell - Washington University School of Medicine, Missouri, USA

Dostarlimab chemo combination for primary advanced or recurrent endometrial cancer ( Prof Matthew Powell - Washington University School of Medicine, Missouri, USA )

FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial...

Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain

FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer ( Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain )

2L triple metronomic chemo shows more efficacy in comparison to systemic...

Dr Rushabh Kiran Kothari (PI, CRSF group) - Narayana Multispeciality Hospital...

2L triple metronomic chemo shows more efficacy in comparison to systemic therapy for head and neck cancer ( Dr Rushabh Kiran Kothari (PI, CRSF group) - Narayana Multispeciality Hospital, Ahmedabad, India )

Next-generation selective RET inhibitor shows initial promise with RET-altered...

Prof Qing Zhou - Guangdong Provincial People’s Hospital, Guangzhou, China

Next-generation selective RET inhibitor shows initial promise with RET-altered solid tumours ( Prof Qing Zhou - Guangdong Provincial People’s Hospital, Guangzhou, China )

ASCO 2023: Breast cancer research highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2023: Breast cancer research highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Ciltacabtagene autoleucel greatly reduces risk of disease progression in...

Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA

$Ciltacabtagene autoleucel greatly reduces risk of disease progression in lenalidomide-refractory MM ( Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA )$

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

ASCO 2023: Head and neck highlights

Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA

ASCO 2023: Head and neck highlights ( Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer